A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

NCT07726212 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Esophageal Cancer
Advanced Lung Cancer

Interventions

DRUG: MC002（ADC）

Sponsor

Hangzhou MacroLink Biopharmaceutical LLC